Chester County News and Community Website
BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced the successful completion of a full study on its localized pain management product, Probudur™, conducted in partnership with the U.S. Army …
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced that Matthew Barnes, the company’s senior director of portfolio management, will be presenting at the Outsourcing in Clinical Trials (OCT) Conference. …
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has reported encouraging results from a minipig Dose Range Finding (DRF) study for Probudur, its long-acting liposomal bupivacaine injection. Designed to provide …
Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), a division …
Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its financial results for the second quarter ending June 30, 2024, alongside notable advancements in its product pipeline and strategic initiatives.
Virpax Pharmaceuticals Reports Q2 2024 Financial Results and Strategic Progress Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) will participate in the Sidoti August Virtual Investor Conference. CEO Gerald W. Bruce and CFO Vinay Shah will present and host one-on-one …
Virpax Pharmaceuticals to Present at Sidoti August Virtual Investor Conference Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq’s minimum bid price requirement as of July 24, 2024. This achievement follows a formal notice from Nasdaq’s …
Virpax Pharmaceuticals Regains Nasdaq Compliance Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced positive results from a pilot study using a swine model for Probudur, its long-acting pain relief drug. Probudur, a liposomal …
Virpax Pharmaceuticals Reports Promising Results for Pain Relief Drug Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently released its financial results for the first quarter of 2024, revealing increased losses as the company advances its drug development programs.
Virpax Pharmaceuticals Reports Increased Losses Amid Promising Developments Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) has unveiled hopeful results from its Maximum Tolerated Dose (MTD) study of Probudur™, a long-acting pain management drug, in Sprague-Dawley rats. Probudur, …
Virpax Pharmaceuticals’ Probudur Shows Promising Results in Pain Management Study Read More